Company Analysis
Sign in

Arcutis Biotherapeutics, Inc. (ARQT)

Nasdaq: ARQT · Pharmaceutical Preparations · Westlake Village, CA · filing with the SEC since 2019
Full chart Alerts Compare
Grade6.4
◀ Past 6.7● Present 6.8▶ Future 5.5
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

32 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Arcutis Biotherapeutics, Inc.’s names, not what it holds today.

Patents granted
32
32 utility, 1976 to Dec 31, 2025
Granted in 2025
8
Against 11 in 2024 and 5 in 2023
Applications published
59
12 of them in 2025
Names they are printed under
3
its own name, a former name
By yearGrantedApplications published
'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals27
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
ARCUTIS BIOTHERAPEUTICS, INC. its own name
US, as the owner printed on each patent
26 granted
51 published
Arcutis, Inc. a former name
US, as the owner printed on each patent
6 granted
7 published
ARCUTIS BIOTHERAPEUTICS, INC. its own name
named as the applicant on its applications, in US. 3 more under the same name are not counted (printed in CA)
0 granted
1 published
Names not counted (2)
Ducentis Biotherapeutics Ltd.
Most of its patents print GB; this name counts in CA. 1 granted and 1 published under it are not counted.
Ducentis Biotherapeutics Ltd.
Most of its patents print GB; this name counts in CA. 0 granted and 2 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 4, 202512,458,652Pharmaceutical compositions of spironolactone for deep dermal drug deliveryPharmaceuticalsARCUTIS BIOTHERAPEUTICS, INC.
Oct 28, 202512,453,721Topical roflumilast aerosol foamsPharmaceuticalsARCUTIS BIOTHERAPEUTICS, INC.
Aug 19, 202512,390,453Method for reducing side effects from administration of phosphodiesterase-4 inhibitorsPharmaceuticalsARCUTIS BIOTHERAPEUTICS, INC.
Jun 24, 202512,336,983Inhibition of crystal growth of roflumilastPharmaceuticalsARCUTIS BIOTHERAPEUTICS, INC.
Jun 17, 202512,329,751Topical roflumilast formulation having antifungal propertiesPharmaceuticalsARCUTIS BIOTHERAPEUTICS, INC.
May 27, 202512,310,956Topical roflumilast formulation having improved delivery and plasma half-lifePharmaceuticalsARCUTIS BIOTHERAPEUTICS, INC.
Mar 25, 202512,257,242Inhibition of crystal growth of roflumilastPharmaceuticalsARCUTIS BIOTHERAPEUTICS, INC.
Feb 11, 202512,220,409Roflumilast formulations with an improved pharmacokinetic profilePharmaceuticalsARCUTIS BIOTHERAPEUTICS, INC.
Dec 10, 202412,161,643Stable formulations of SHR0302PharmaceuticalsARCUTIS BIOTHERAPEUTICS, INC.
Nov 19, 202412,144,802Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drugPharmaceuticalsARCUTIS BIOTHERAPEUTICS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 20, 20252025/0352526TOPICAL ROFLUMILAST FORMULATION HAVING ANTIFUNGAL PROPERTIESPharmaceuticalsARCUTIS BIOTHERAPEUTICS, INC.
Oct 9, 20252025/0312457PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST IN AQUEOUS BLENDS OF WATER-MISCIBLE, PHARMACEUTICALLY ACCEPTABLE SOLVENTSPharmaceuticalsARCUTIS BIOTHERAPEUTICS, INC.
Sep 18, 20252025/0288569METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORSPharmaceuticalsARCUTIS BIOTHERAPEUTICS, INC.
Sep 11, 20252025/0281471TOPICAL ROFLUMILAST FORMULATION HAVING IMPROVED DELIVERY AND PLASMA HALF- LIFEPharmaceuticalsARCUTIS BIOTHERAPEUTICS, INC.
Jul 24, 20252025/0235435INHIBITION OF CRYSTAL GROWTH OF ROFLUMILASTPharmaceuticalsARCUTIS BIOTHERAPEUTICS, INC.
May 8, 20252025/0144084PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST AND SOLVENTS CAPABLE OF DISSOLVING HIGH AMOUNTS OF THE DRUGPharmaceuticalsARCUTIS BIOTHERAPEUTICS, INC.
Apr 24, 20252025/0127767Roflumilast Formulations with an Improved Pharmacokinetic ProfilePharmaceuticalsARCUTIS BIOTHERAPEUTICS, INC.
Mar 20, 20252025/0090535STABLE FORMULATIONS OF SHR0302PharmaceuticalsARCUTIS BIOTHERAPEUTICS, INC.
Mar 20, 20252025/0090509METHODS OF REDUCING ITCH USING TOPICAL ROFLUMILAST COMPOSITIONSPharmaceuticalsARCUTIS BIOTHERAPEUTICS, INC.
Mar 20, 20252025/0090508METHODS OF REDUCING ITCH USING TOPICAL ROFLUMILAST COMPOSITIONSPharmaceuticalsARCUTIS BIOTHERAPEUTICS, INC.
What it applied for, 2024 to 2025: Pharmaceuticals 24.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ARQT · research, not advice